NDAORALTABLET
Approved
Dec 2002
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
5/8 — Partial
ADVIL ALLERGY SINUS (chlorpheniramine maleate, ibuprofen, pseudoephedrine hcl) by GSK is cyclooxygenase inhibitors [moa]. Approved for these symptoms associated with hay fever, other upper respiratory allergies, the common cold: runny nose itchy and 3 more indications. First approved in 2002.
Drug data last refreshed 59m ago · AI intelligence enriched 4h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADVIL ALLERGY SINUS is a fixed-dose combination oral tablet containing ibuprofen (NSAID), chlorpheniramine maleate (antihistamine), and pseudoephedrine HCL (decongestant). It treats symptoms of allergic rhinitis, upper respiratory allergies, and the common cold including nasal congestion, sneezing, headache, and minor aches. The ibuprofen component works via cyclooxygenase inhibition to reduce inflammation and pain.
LOE Approaching5mo to LOE
Product is approaching loss of exclusivity with minimal remaining patent life; brand teams face shrinking market opportunity and resource reallocation toward pipeline assets.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Worked on ADVIL ALLERGY SINUS at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.